SN 10XX
Alternative Names: STC-10XXLatest Information Update: 29 Jan 2026
At a glance
- Originator Brenus Pharma
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Jan 2026 Early research in Cancer in France (Parenteral), before January 2026 (Brenus Pharma pipeline, January 2026)